The Academy of Managed Care Pharmacy (AMCP) will be hosting a new conference, Nexus 2013, October 15-18 in San Antonio, Texas. Nexus 2013 will aim to simplify the complex healthcare system and find new and innovative solutions by bringing together people from both sides of the equation. The new conference will be replacing AMCP’s Education Conference.
The Academy of Managed Care Pharmacy (AMCP) will be hosting a new conference, Nexus 2013, October 15-18 in San Antonio, Texas. Nexus 2013 will aim to simplify the complex healthcare system and find new and innovative solutions by bringing together people from both sides of the equation. The new conference will be replacing AMCP’s Education Conference.
Attendees will have the opportunity to attend 2 “Innovative Interchange Sessions,” and in-depth 3 hour sessions, which are new to the conference, will provide information about healthcare reform and solutions to the challenges of chronic diseases. Those interested in the drug pipeline can attend 2 sessions: Specialty Pharmaceuticals in Development or Brand and Generic Drug in Development.
Nexus 2013 will feature 4 program tracks: specialty pharmacy, healthcare reform, clinical breakthroughs, and research in managed care. Each track will feature a number of informative sessions and the Healthcare Reform track will feature a Spotlight Session. According to AMCP, the education sessions will have more opportunities for active learning and audience interaction than previous education conferences.
Pharmacy students will have the option to attend 2 special sessions, both developed especially for students, at the conference. Residents will have a chance to participate in a Managed Care Pharmacy Residency Showcase.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More